Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...

System of Care to Advance Care for the Most Commonly Inherited Heart DiseaseSOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- ...

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common ...

Discover why Cytokinetics (CYTK) is a top BUY in precision cardiology. Learn about aficamten, its market potential, and ...

BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

You've disabled cookies in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing ...

Patients with undiagnosed sleep disordered breathing and hypertrophic cardiomyopathy may have subclinical myocardial injury.

BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage ...

Right now, the HALT Study is underway to provide the substantial evidence of effectiveness necessary for the full FDA approval of Felycin-CA1 (referred to as TRIV202 in HALT) for the management of ...

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and impacts an estimated 1 in 500 people in the ...